Fosun Pharma Acquires Controlling Stake in Green Valley Pharma; Sanofi's BTK Inhibitor Fails Phase 3 Trial in PPMS

© Amino Observation - Innovative Drug Team Original Production

Author | Zheng Xiao

/ 01 /

Market Express

1) Everest Medicines Releases 2030 Strategy

On December 15, Everest Medicines officially released its 2030 development strategy, comprehensively planning the blueprint for the next five years, continuously enriching its product pipeline, maximizing the value of its commercial platform, and advancing the globalization of its R&D layout.

2) Fosun Pharmaceutical Announces Controlling Acquisition of Green Valley Pharmaceutical

On December 15, Fosun Pharmaceutical announced that its subsidiary, Fosun Pharmaceutical Industry, signed an investment agreement with Green Valley Pharmaceutical and its existing shareholders. Fosun Pharmaceutical plans to invest approximately RMB 1.412 billion to acquire a controlling stake in Green Valley Pharmaceutical. After the completion of this acquisition, Green Valley Pharmaceutical will become a subsidiary of Fosun Pharmaceutical, and its core product, Sodium Oligomannate Capsules, will be integrated into Fosun Pharmaceutical's innovative drug pipeline, mainly for the treatment of mild to moderate Alzheimer's disease.

1) Directors and Major Shareholders of Everest Medicines Increase Their Stake in the Company

On December 15, Everest Medicines announced that on December 12, 2025, Mr. Fu Wei, Non-Executive Director, Honorary Chairman of the Board, and a major shareholder of the company; Mr. Wu Yifang, Executive Director and Chairman of the Board; Mr. Luo Yongqing, Executive Director and Chief Executive Officer of the company; and Mr. He Ying, Executive Director, President, and Chief Financial Officer of the company, collectively purchased 846,659 ordinary shares of the company through the open market. The total amount involved exceeded 38 million Hong Kong dollars, with an average price of approximately HK$45.01 per share. In addition, CBC Group, a major shareholder of the company, has further committed to increasing its shareholding by no more than 1% cumulatively over the next three to six months, subject to market conditions and applicable legal and regulatory restrictions.

1) Johnson & Johnson's JNJ-95597528 Injection Receives Clinical Approval

On December 15, according to the CDE website, Johnson & Johnson's JNJ-95597528 injection received clinical approval for the treatment of adult patients with moderate to severe atopic dermatitis who are not adequately controlled by topical medications or are unsuitable for such treatments.

2) Haisi Shengnuo Pharmaceutical HSK50042 Tablets Obtain Clinical Approval

On December 15, according to the CDE official website, Haisi Shengnuo Pharmaceutical's HSK50042 tablet received clinical approval and is proposed to conduct research for the treatment of idiopathic pulmonary fibrosis.

1) Sanofi's BTK Inhibitor Fails in Phase 3 Clinical Trial for ppMS

On December 15, Sanofi announced that the PERSEUS Phase 3 study results showed that the BTK inhibitor tolisbrutinib did not meet its primary endpoint in delaying the time to 6-month confirmed composite disability progression in patients with primary progressive multiple sclerosis (PPMS). PPMS patients account for approximately 10% of the overall multiple sclerosis patient population. Based on these results, Sanofi will not pursue regulatory registration of tolisbrutinib for the PPMS indication.

PS: Welcome to scan the QR code below to add Amino's WeChat for communication.